Congress mandates free opioid treatment—removing a barrier to recovery
S. 2072 — MORE Savings Act · Filed by Richard Blumenthal (D-CT) · 5 cosponsors · Introduced Jun 12, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires Medicare, private health insurance, and employer plans to cover opioid-use-disorder medications (including overdose reversal drugs), behavioral health treatment, and recovery support services without any patient cost-sharing (copays, coinsurance, deductibles). It also establishes a Medicare pilot program in 15 high-need states and increases federal Medicaid reimbursement to 90% for medication-assisted treatment and recovery services.
Why we flagged it
The bill's core mechanism is a mandate requiring health plans and Medicare to cover opioid-use-disorder treatment without cost-sharing. This is a direct regulatory requirement on payers, not a subsidy or carve-out; it shifts financial burden from patients to insurers and the federal government.
What the text implies
- Removal of cost-sharing may increase utilization of medication-assisted treatment, potentially reducing emergency department visits and overdose deaths, but implementation costs and insurer responses (e.g., prior authorization, network restrictions) are not addressed.
- The 90% federal Medicaid match for MAT and recovery services creates a permanent fiscal incentive for states to expand coverage, but the bill does not specify funding source or cap total federal liability.
The full analysis lists 4 implications of this text.
Who stands to gain
medication-assisted treatment providers; behavioral health and addiction treatment facilities; peer support and recovery service organizations